Citations

Clear

4610 citation(s) found for "Lu, Brian".

Blood volume and chronic kidney disease in heart failure – Can volume expansion help balance the Cardio‐Renal Axis for better clinical outcomes?
Miller, Wayne L. , Fudim, Marat , Mullan, Brian P., Miller, Wayne L.

Mayo Clinic

Physiological Reports | December 3, 2022 | Volume: 10 | Issue: 23 | Pages: No page available

10.14814/phy2.15526 | PMID 36461656 Get It

AbstractIntravascular volume is largely regulated by the kidneys but how differences in intravascular volume profiles interact with chronic kidney disease (CKD) to influence outcomes in chronic heart failure (HF) has not been explored. Our hypothesis was that a greater degree of volume expansion (VE) would moderate the impact of CKD on HF‐related clinical outcomes. Quantitative blood volume (BV) data were available in 137 patients at the time of hospital discharge using a nuclear medicine radiolabeled albumin indicator‐dilution technique. The study patients were stratified by the cohort median glomerular filtration rate (GFR, 44 ml/min/1.73 m2). An a priori cut‐point of ≥+25% above normal BV was then used to further stratify the two GFR subgroups and prospectively analyzed for 1‐year HF‐related mortality or 1st re‐hospitalization. Persistent BV expansions ≥+25% were present in 51% of the cohort. In the subgroup with GFR above the median (N = 68) greater or lesser BV expansion from +25% did not differentiate outcomes. However, in the subgroup with GFR below the median (N = 69), BV expansion‐stratified risk (log‐rank p = 0.022) with <+25% VE associated with poorer outcomes, while VE ≥ + 25% was associated with lower risk and comparable to GFR above the median. In patients with chronic HF, significant intravascular VE and CKD are common co‐existing conditions. The presence of larger VE, however, appears to be a factor mitigating the impact of declining renal function on clinical outcomes, and as an element of volume pathophysiology warrants further study.
Clinician and Algorithmic Application of the 2019 and 2022 Society of Cardiovascular Angiography and Intervention Shock Stages in the Critical Care Cardiology Trials Network Registry
Patel, Siddharth M. , Berg, David D. , Bohula, Erin A. , Baird-Zars, Vivian M., Barnett, Christopher F. , Barsness, Gregory W. , Chaudhry, Sunit‐Preet , Daniels, Lori B. , Diepen, Sean van , Goldfarb, Michael , Katz, Jason N. , Kenigsberg, Benjamin B. , Lawler, Patrick R. , Miller, P. Elliott , Papolos, Alexander , Park, Jeong‐Gun , Prasad, Rajnish, Teuteberg, Jeffrey J. , Investigators, on behalf of the CCCTN, Goldfarb, Michael , van Diepen, Sean , Goldfarb, Michael , Jentzer, Jacob C , Lawler, Patrick , Miller, P Elliott , Potter, Brian J , Singam, N Sarma V , Solomon, Michael A , Teuteberg, Jeffrey J , Morrow, David A , Goldfarb, Michael , Daniels, Lori B , Bohula, Erin A , Berg, David , Patel, Siddharth M , Ghafghazi, Shahab , Jentzer, Jacob C. , Prasad, Rajnish, Singam, Narayana Sarma V. , Sinha, Shashank S , Solomon, Michael A. , Morrow, David A. , Investigators, on behalf of the CCCTN

Mayo Clinic

Circulation: Heart Failure | December 2, 2022 | Volume: 16 | Issue: 1 | Pages: No page available

10.1161/circheartfailure.122.009714 | PMID 36458542 Get It

Background: Algorithmic application of the 2019 Society of Cardiovascular Angiography and Intervention (SCAI) shock stages effectively stratifies mortality risk for patients with cardiogenic shock. However, clinician assessment of SCAI staging may differ. Moreover, the implications of the 2022 SCAI criteria update remain incompletely defined. Methods: The Critical Care Cardiology Trials Network is a multicenter registry of cardiac intensive care units (CICUs). Between 2019 and 2021, participating centers (n=32) contributed at least a 2-month snapshot of consecutive medical CICU admissions. In-hospital mortality was assessed across 3 separate staging methods: clinician assessment, Critical Care Cardiology Trials Network algorithmic application of the 2019 SCAI criteria, and a revision of the Critical Care Cardiology Trials Network application using the 2022 SCAI criteria. Results: Of 9612 admissions, 1340 (13.9%) presented with cardiogenic shock with in-hospital mortality of 35.2%. Both clinician and algorithm-based staging using the 2019 SCAI criteria identified a stepwise gradient of mortality risk (stage C–E: 19.0% to 83.7% and 14.6% to 52.2%, respectively; P trend <0.001 for each). Clinician assignment of SCAI stages identified higher risk patients compared with algorithm-based assignment (stage D: 49.9% versus 29.3%; stage E: 83.7% versus 52.2%). Algorithmic application of the 2022 SCAI criteria, with incorporation of the vasoactive-inotropic score, more closely approximated clinician staging (mortality for stage C-E: 21.9% to 70.5%; P trend <0.001). Conclusions: Both clinician and algorithm-based application of the 2019 SCAI stages identify a stepwise gradient of mortality risk, although clinician-staging may better allocate higher risk patients into advanced SCAI stages. Updated algorithmic staging using the 2022 SCAI criteria and vasoactive-inotropic score further refines risk stratification.
Comprehensive evaluation of human-derived anti-poly-GA antibodies in cellular and animal models of C9orf72 disease
Jambeau, Mélanie, Meyer, Kevin D. , Tabet, Ricardos, Lee, Chao-Zong , Ray-Soni, Ananya, Aguilar, Corey, Savage, Kitty, Mishra, Nibha, Cavegn, Nicole, Borter, Petra, Lin, Chun-Chia , Jansen‐West, Karen , Freyermuth, Fernande, Pérez‐Berlanga, Manuela , Jiang, Xin, Daughrity, Lilian M., Pereira, João D. , Narayanan, Sarav, Gu, Yuanzheng , Dhokai, Shekhar, Dalkilic-Liddle, Isin, Maniecka, Zuzanna, Weber, Julien, McAlonis‐Downes, Melissa , Berezovski, Eugene, Zhang, Yong-Jie, Wainger, Brian J. , Kankel, Mark W. , Rushe, Mia, Höck, Christoph, Nitsch, Roger M., Cleveland, Don W. , Petrucelli, Leonard , Polymenidou, Magdalini , Lagier‐Tourenne, Clotilde , Zhang, Yong‐Jie , Zhang, Yong-Jie , Lagier-Tourenne, Clotilde , Jiang, Xin , Zhang, Yong-Jie , Hruška-Plocháň, Marián , Ray-Soni, Ananya, Mishra, Nibha, Li, Nan , Rossi, Pierre De , Daughrity, Lilian M., Workman, Michael J. , Berry, James D. , Gendron, Tania F. , Montrasio, Fabio , Grimm, Jan

Mayo Clinic

Proceedings of the National Academy of Sciences | December 1, 2022 | Volume: 119 | Issue: 49 | Pages: No page available

10.1073/pnas.2123487119 | PMID 36454749 Get It

Hexanucleotide G 4 C 2 repeat expansions in the C9orf72 gene are the most common genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia. Dipeptide repeat proteins (DPRs) generated by translation of repeat-containing RNAs show toxic effects in vivo as well as in vitro and are key targets for therapeutic intervention. We generated human antibodies that bind DPRs with high affinity and specificity. Anti-GA antibodies engaged extra- and intra-cellular poly-GA and reduced aggregate formation in a poly-GA overexpressing human cell line. However, antibody treatment in human neuronal cultures synthesizing exogenous poly-GA resulted in the formation of large extracellular immune complexes and did not affect accumulation of intracellular poly-GA aggregates. Treatment with antibodies was also shown to directly alter the morphological and biochemical properties of poly-GA and to shift poly-GA/antibody complexes to more rapidly sedimenting ones. These alterations were not observed with poly-GP and have important implications for accurate measurement of poly-GA levels including the need to evaluate all centrifugation fractions and disrupt the interaction between treatment antibodies and poly-GA by denaturation. Targeting poly-GA and poly-GP in two mouse models expressing G 4 C 2 repeats by systemic antibody delivery for up to 16 mo was well-tolerated and led to measurable brain penetration of antibodies. Long-term treatment with anti-GA antibodies produced improvement in an open-field movement test in aged C9orf72 450 mice. However, chronic administration of anti-GA antibodies in AAV-(G 4 C 2 ) 149 mice was associated with increased levels of poly-GA detected by immunoassay and did not significantly reduce poly-GA aggregates or alleviate disease progression in this model.
Killian Jamieson Diverticulum, the Great Mimicker: A Case Series and Contemporary Review
Howell, Rebecca J. , Tang, Alice L. , Allen, Jacqui , Altaye, Mekibib , Bayan, Semirra L. , Belafsky, Peter C. , Cervenka, Brian , deSilva, Brad W. , Dion, Gregory R. , Ekbom, Dale C. , Friedman, Aaron D. , Fritz, Mark A. , Giliberto, John Paul , Harmon, Jeffrey , Kasperbauer, Jan L. , Khosla, Sid , Kim, Brandon , Kuhn, Maggie A. , Madden, Lyndsay L. , Matrka, Laura , Mayerhoff, Ross , Piraka, Cyrus , Rosen, Clark A. , Wahab, Shaun A. , Wilson, Keith , Wright, Stephen C. , Young, VyVy N. , Yuen, Sonia , Postma, Gregory N. , Howell, Rebecca , Bayan, Semirra, Belafsky, Peter , deSilva, Brad , Dion, Greg , Ekbom, Dale , Giliberto, John Paul , Kasperbauer, Jan , Kuhn, Maggie , Matrka, Laura , Mayerhoff, Ross , Rosen, Clark , Tabangin, Meredith , Young, Vyvy , Yuen, Sonia , Bayan, Semirra , Amin, Milan R , Guardiani, Elizabeth , Kwak, Paul E. , Ma, Yue , Tabangin, Meredith E. , Wilson, Keith, Wright, S. Carter

Mayo Clinic

The Laryngoscope | December 1, 2022 | Volume: 133 | Issue: 9 | Pages: 2110-2115

10.1002/lary.30508 | PMID 36453465 Get It

ObjectiveTo assess barium esophagram (BAS) as a diagnostic marker for patients with Killian Jamieson diverticula (KJD).MethodsProspective, multicenter cohort study of individuals enrolled in the Prospective OUtcomes of Cricopharyngeus Hypertonicity (POUCH) Collaborative. Patient demographics, comorbidities, radiographic imaging reports, laryngoscopy findings, patient‐reported outcome measures (PROM), and operative reporting were abstracted from a REDCap database and summarized using means, medians, percentages, frequencies. Paired t‐tests and Wilcoxon Signed Rank test were used to test pre‐ to post‐operative differences in RSI, EAT‐10, and VHI‐10 scores. Diagnostic test evaluation including sensitivity, specificity, positive, and negative predictive value with 95% confidence intervals were calculated comparing BAS findings to operative report.ResultsA total of 287 persons were enrolled; 13 (4%) patients were identified with confirmed KJD on operative reports. 100% underwent open transcervical excision. BAS has a 46.2% (95% confidence interval [CI]: 23.2, 70.9) sensitivity and 97.8% (95% CI: 95.3, 99.0) specificity in detecting a KJD and 50% (95% CI: 25.4, 74.6) positive predictive value but 97.4% (95%CI: 94.8, 98.7) negative predictive value. Preoperatively, patients reported mean (SD) RSI and EAT‐10 of 19.4 (9) and 8.3 (7.5) accordingly. Postoperatively, patients reported mean (SD) RSI and EAT‐10 as 5.4 (6.2) and 2.3 (3.3). Both changes in RSI and EAT‐10 were statistically significant (p = 0.008, p = 0.03).ConclusionKJD are rare and represent <5% of hypopharyngeal diverticula undergoing surgical intervention. Open transcervical surgery significantly improves symptoms of dysphagia. BAS has high specificity but low sensitivity in detecting KJD.Level of Evidence4 Laryngoscope, 133:2110–2115, 2023
Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial
Kumar, Shaji , Alsina, Melissa , LaPlant, Betsy, Badros, Ashraf , Abonour, Rafat , Asmus, Erik, Dhakal, Binod , Rosenbaum, Cara A. , Egan, Daniel , Bhutani, Manisha , Durie, Brian G.M. , Abdallah, Al-Ola , Dhakal, Binod , Jakubowiak, Andrzej

Mayo Clinic

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1830-1832

10.1182/blood-2022-168930 Get It

Validation of a Novel Rac1 Inhibitor As Potent Secdrug Against Activating Ras Mutant and Drug-Resistant Multiple Myeloma
Ahmed, Salsabil, Wiesen, Lisa, Sharma, Neeraj , Mukherjee, Ujjal Kumar , Kumar, Shaji , Ness, Brian G. Van , Sharma, Neeraj , Mazumder, Suman , Baughn, Linda B. , Mitra, Amit

Mayo Clinic

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 4249-4250

10.1182/blood-2022-164501 Get It

Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era
Mwangi, Raphael , Nowakowski, Grzegorz S. , Thompson, Carrie A. , Desai, Sanjal H. , Wang, Yucai , Farooq, Umar , Mou, Eric , Feldman, Andrew L. , Syrbu, Sergei , Slager, Susan L. , Maurer, Matthew J. , Kay, Neil E. , Habermann, Thomas M. , Link, Brian K. , Cerhan, James R.

Mayo Clinic

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1934-1936

10.1182/blood-2022-165207 Get It

Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Inte
Mian, Agrima , Yi, Jean C. , Preussler, Jaime M. , Hill, Brian T. , Černý, Jan , Deol, Abhinav , Hahn, Theresa , Hashmi, Shahrukh K. , Khera, Nandita , Loren, Alison W. , Stiff, Patrick J. , Uberti, Joseph P., Whalen, Victoria , Reynolds, Jana , Syrjala, Karen L. , Hamilton, Betty K. , Wei, Wei , Chakraborty, Rajshekhar , Jaglowski, Samantha , Jim, Heather , McGuirk, Joseph P. , Savani, Bipin N. , Wingard, John R. , Holtan, Shernan G. , Wood, William A. , Baker, Kevin Scott , Majhail, Navneet S.

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 8019-8021

10.1182/blood-2022-167411 Get It